|  | Cancer | Lymphoma

Mantle Cell Lymphoma: Post-Diagnosis Roadmap from Staging to Survivorship

Mantle Cell Lymphoma (MCL) is an aggressive B-cell NHL (t(11;14)/CCND1). A structured roadmap navigates the complex journey from diagnosis through long-term management.

Stepwise Pathway

  1. Comprehensive Staging:
    • PET-CT (baseline metabolic assessment)
    • BM biopsy + aspirate (flow, FISH, karyotype)
    • Lumbar puncture (if CNS symptoms or high-risk: blastoid, Ki-67 >30%, elevated LDH)
    • ECHO, MUGA, pulmonary function (baseline for anthracycline)
    • MIPI / MIPI-c (prognostic index: age, ECOG, LDH, WBC, Ki-67)
  2. Multidisciplinary Review: Hematology, pathology, radiology, radiation oncology, transplant, genetics.
  3. First-Line Therapy Selection:
    • Fit (MIPI Low/Int): R-CHOP/R-DHAP alternating → Consolidation: Auto-HSCT (standard) ± Rituximab maintenance. Consider Nordic MCL2/3 (alternating R-maxi-CHOP/R-high-dose-AraC) → Auto-HSCT.
    • Unfit / Elderly: R-Bendamustine ± maintenance; or BTKi (ibrutinib/acalabrutinib/zanubrutinib) based — emerging 1L data.
  4. Response Assessment: PET-CT (Deauville 1–3 = CMR/PDR); BM if PET-negative.
  5. Consolidation & Maintenance: Auto-HSCT in CR/PR → Rituximab maintenance q2mo × 2–3 yr (PROLONG/MCL-002). MRD monitoring (NGS/flow) guides duration.
  6. Relapse Management:
    • BTKi (if naïve) — high response, continuous.
    • Pirtobrutinib (non-covalent BTKi) — post-covalent BTKi.
    • CAR-T (brexucabtagene) — 3L+, high CR rate.
    • Bispecifics, BTK degraders, clinical trials.
  7. Long-Term Survivorship: Secondary cancer screening, cardiac (anthracycline), thyroid (neck RT), immunizations, QoL, psychosocial.

Key Message

MCL is treatable; cure fraction exists with intensive frontline + auto-HSCT. Novel agents transform relapse landscape. Expert center care improves outcomes.

Lymphoma - Related Articles